title: Rosuvastatin Decreases Mean Platelet Volume in Patients With Diabetes Mellitus.
abstract: Statins have multiple effects (also known as pleiotropic effects) on inflammation, plaque stabilization, endothelial function, and hemostasis. We evaluated the effects of rosuvastatin on mean platelet volume (MPV)--a marker for platelet activity--in patients with diabetes mellitus (DM) on rosuvastatin medication. Patients (n = 178) who were to be prescribed high-intensity rosuvastatin were retrospectively enrolled according to their medical records. Baseline and 6-month biochemical tests, automated blood count, cell-volume analysis, and their cardiovascular risk factors were recorded. Rosuvastatin significantly reduced the MPV and the lipid parameters including total cholesterol, triglyceride, and low-density lipoprotein cholesterol (LDL-C). However, there was no correlation between MPV and LDL-C before (r = -.66; P = .383) and after (r = -.112; P = .135) rosuvastatin treatment or between ΔMPV and ΔLDL-C after 40 mg rosuvastatin daily therapy (r = -.155; P = .073). Rosuvastatin significantly decreases the MPV as well as cholesterol levels. The antiplatelet activation properties of high-dose rosuvastatin treatment in patients with DM are not lipid dependent.
authors.affiliation: Department of Cardiology, Faculty of Medicine, Namik Kemal University, Tekirdag, Turkey ayakyuzq5@gmail.com.
authors.forename: Aydın
authors.initials: A
authors.lastname: Akyüz
authors.affiliation: Department of Cardiology, Faculty of Medicine, Namik Kemal University, Tekirdag, Turkey.
authors.forename: Dursun Çayan
authors.initials: DÇ
authors.lastname: Akkoyun
authors.affiliation: Department of Cardiology, Faculty of Medicine, Namik Kemal University, Tekirdag, Turkey.
authors.forename: Hasan
authors.initials: H
authors.lastname: Değirmenci
authors.affiliation: Department of Internal Medicine, Faculty of Medicine, Namik Kemal University, Tekirdag, Turkey.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Oran
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers; D001792:Blood Platelets / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000175:diagnosis; D050171:Dyslipidemias / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D063847:Mean Platelet Volume; D008499:Medical Records; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012189:Retrospective Studies; D000068718:Rosuvastatin Calcium / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D015415:Biomarkers; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D014280:Triglycerides; D000068718:Rosuvastatin Calcium; D002784:Cholesterol
keywords: cholesterol; diabetes mellitus; mean platelet volume; rosuvastatin